Literature DB >> 30259909

Adenocarcinoma classification: patterns and prognosis.

E Kuhn1, P Morbini2, A Cancellieri3, S Damiani4, A Cavazza5, C E Comin6.   

Abstract

Lung cancer is the most frequent human malignancy and the principal cause of cancer-related death worldwide. Adenocarcinoma is now the main histologic type, accounting for almost half of all the cases. The 2015 World Health Organization has adopted the classification recently developed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society. This new adenocarcinoma classification has incorporated up-to-date advances in radiological, molecular and oncological knowledge, providing univocal diagnostic criteria and terminology. For resection specimens, new entities have been defined such as adenocarcinoma in situ and minimally invasive adenocarcinoma to designate adenocarcinomas, mostly nonmucinous and ≤ 3 cm in size, with either pure lepidic growth or predominant lepidic growth with ≤ 5 mm invasion, respectively. For invasive adenocarcinoma, the new classification has introduced histological subtyping according to the predominant pattern of growth of the neoplastic cells: lepidic (formerly non mucinous brochioloalveolar adenocarcinoma), acinar, papillary, micropapillary, and solid. Of note, micropapillary pattern is a brand new histologic subtype. In addition, four variants of invasive adenocarcinoma are recognized, namely invasive mucinous (formerly mucinous brochioloalveolar adenocarcinoma), colloid, fetal, and enteric. Importantly, three variants that were considered in the previous classification have been eliminated, specifically mucinous cystadenocarcinoma, signet ring cell, and clear cell adenocarcinoma. This review presents the changes introduced by the current histological classification of lung adenocarcinoma and its prognostic implications.
Copyright © 2018 Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.

Entities:  

Keywords:  Adenocarcinoma; Classification; Lung; Pathology; Prognosis

Mesh:

Year:  2018        PMID: 30259909

Source DB:  PubMed          Journal:  Pathologica        ISSN: 0031-2983


  22 in total

1.  ETV4 mediated lncRNA C2CD4D-AS1 overexpression contributes to the malignant phenotype of lung adenocarcinoma cells via miR-3681-3p/NEK2 axis.

Authors:  Binliang Wang; Yuanyuan Cai; Xiaobo Li; Yiming Kong; Haiwei Fu; Jianying Zhou
Journal:  Cell Cycle       Date:  2021-12-01       Impact factor: 4.534

2.  Mechanism of Key Ingredient of Astragalus membranaceus on Lung Adenocarcinoma via PI3K/AKT Signaling Clarified by Utilizing Network Pharmacology Approach and Experimental Validation.

Authors:  Yuan-Chun Wang; Jian-Rong Hui; Gang Xiao; Qiao-Lin Ma
Journal:  Chin J Integr Med       Date:  2022-08-31       Impact factor: 2.626

3.  Cancer-Testis Antigen LDH-C4 in Tissue, Serum, and Serum-Derived Exosomes Serves as a Promising Biomarker in Lung Adenocarcinoma.

Authors:  Wei Peng; Jin Chen; Yanping Xiao; Guangjian Su; Yan Chen; Zhaolei Cui
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

4.  Correlation of computed tomography quantitative parameters with tumor invasion and Ki-67 expression in early lung adenocarcinoma.

Authors:  Hao Dong; Lekang Yin; Cuncheng Lou; Junjie Yang; Xinbin Wang; Yonggang Qiu
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

5.  DNA repair genes are associated with tumor tissue differentiation and immune environment in lung adenocarcinoma: a bioinformatics analysis based on big data.

Authors:  Jiayin Li; Jingxu Zhou; Jing Zhang; Zhiwei Xiao; Wenping Wang; Hanrui Chen; Lizhu Lin; Qiuye Yang
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 3.005

6.  Quaking 5 suppresses TGF-β-induced EMT and cell invasion in lung adenocarcinoma.

Authors:  Shengjie Wang; Xin Tong; Chang Li; Ersuo Jin; Zhiyue Su; Zelong Sun; Weiwei Zhang; Zhe Lei; Hong-Tao Zhang
Journal:  EMBO Rep       Date:  2021-03-26       Impact factor: 8.807

7.  Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial.

Authors:  Ping Fang; Liqin Zhang; Xianru Zhang; Jiawen Yu; Jun Sun; Qi-An Jiang; Mingbao Zha; Anastasia P Nesterova; Hongbao Cao
Journal:  Sci Rep       Date:  2019-09-30       Impact factor: 4.379

Review 8.  Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy.

Authors:  Ilaria Guerriero; Gianni Monaco; Vincenzo Coppola; Arturo Orlacchio
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-22

9.  Development and Validation a Nomogram Incorporating CT Radiomics Signatures and Radiological Features for Differentiating Invasive Adenocarcinoma From Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma Presenting as Ground-Glass Nodules Measuring 5-10mm in Diameter.

Authors:  Lili Shi; Weiya Shi; Xueqing Peng; Yi Zhan; Linxiao Zhou; Yunpeng Wang; Mingxiang Feng; Jinli Zhao; Fei Shan; Lei Liu
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

10.  Survival analysis of patients with primary breast duct carcinoma and lung adenocarcinoma: a population-based study from SEER.

Authors:  Fengyuan Lv; Mingliang Cheng; Liang Jiang; Xiaoping Zhao
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.